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Itch/β-arrestin2-dependent non-proteolytic
ubiquitylation of SuFu controls Hedgehog signalling
and medulloblastoma tumorigenesis
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Suppressor of Fused (SuFu), a tumour suppressor mutated in medulloblastoma, is a central
player of Hh signalling, a pathway crucial for development and deregulated in cancer.
Although the control of Gli transcription factors by SuFu is critical in Hh signalling, our
understanding of the mechanism regulating this key event remains limited. Here, we show
that the Itch/β-arrestin2 complex binds SuFu and induces its Lys63-linked polyubiquitylation
without affecting its stability. This process increases the association of SuFu with Gli3,
promoting the conversion of Gli3 into a repressor, which keeps Hh signalling off. Activation of
Hh signalling antagonises the Itch-dependent polyubiquitylation of SuFu. Notably, different
SuFu mutations occurring in medulloblastoma patients are insensitive to Itch activity, thus
leading to deregulated Hh signalling and enhancing medulloblastoma cell growth. Our ﬁnd-
ings uncover mechanisms controlling the tumour suppressive functions of SuFu and reveal
that their alterations are implicated in medulloblastoma tumorigenesis.
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Suppressor of Fused (SuFu) is a tumour suppressor gene andnegative regulator of Hedgehog (Hh) signalling, a conserveddevelopmental pathway crucial for tissue patterning, stem
cell maintenance, and tumorigenesis1–3. The SuFu protein is
localised to both the nucleus and the cytoplasm and controls the
Hh pathway by binding directly to Gli transcription factors, the
ﬁnal effectors of Hh signalling4,5. Three Gli proteins have been
identiﬁed in mammals: Gli1 functions exclusively as a tran-
scriptional activator, whereas Gli2 and Gli3 exist in both full-
length (FL) activator and truncated repressor (R) forms. Recently,
SuFu has emerged as essential for the stabilisation of Gli2FL and
Gli3FL6, protecting them from degradation by the E3 ubiquitin
ligase SPOP. In this context, SuFu regulates the formation of
either the repressor or activator forms of Gli3. In the absence of
Hh signalling, SuFu restrains Gli3 in the cytoplasm, promoting its
processing into the repressor form (Gli3R). Initiation of signalling
induces the dissociation of SuFu from Gli3, preventing the for-
mation of Gli3R. This event allows Gli3 to enter the nucleus,
where it is converted into a labile transcriptional activator7.
However, the mechanism by which the SuFu–Gli interaction is
controlled remains poorly understood.
SuFu is required for mouse embryonic development8,9. Its
genetic inactivation leading to constitutive activation of the Hh
pathway in a ligand-independent manner causes early embryonic
lethality at E9.5 with neural tube defects. In humans, SuFu
mutations are associated with Gorlin’s syndrome, a hereditary
condition characterised by increased risk of developing various
forms of tumours, such as basal cell carcinoma and medullo-
blastoma (MB)10–12. Moreover, SuFu is mutated either in the
germline or somatically in patients with Sonic hedgehog medul-
loblastoma (Shh-MB)10,12–17, a childhood brain tumour asso-
ciated with Hh signalling aberrations. Despite the central role of
SuFu in controlling Hh pathway and its relevance for Hh-
dependent tumorigenesis, little information regarding the
mechanisms that control its activity is available.
Post-translational modiﬁcations, such as phosphorylation and
ubiquitylation, affect SuFu stability. Indeed, Shh signalling pro-
motes ubiquitylation of SuFu leading to its proteasomal degra-
dation18. This process is opposed by SuFu phosphorylation by
glycogen synthase kinase-3β (GSK3β) and cyclic adenosine
monophosphate (cAMP)-dependent protein kinase A (PKA) that
induce SuFu stabilisation19. By means of an enzymatic cascade
involving an activating enzyme (E1), a conjugating enzyme (E2),
and a ligase (E3) that determines substrate selectivity, ubiquitin is
transferred to substrate proteins, generally inducing their degra-
dation by the 26S proteasome20,21. Ubiquitin-dependent events
have emerged as crucial mechanisms by which stability, activity,
or localisation of Gli proteins are controlled3,22,23. Gli ubiquity-
lation is mediated by E3 ligases belonging to the RING-Cullin
family, such as Cullin1-Slimb/βTrCP and Cullin3-HIB/Roadkill/
SPOP24–26, and the HECT family, such as Itch27,28, as well as by
PCAF (P300/CBP-associated factor), a histone acetyltransferase
protein with E3 ubiquitin ligase activity29,30. Ubiquitylation
promoted by these E3 ligases lead to either proteasome-
dependent proteolytic cleavage of the Gli2 and Gli3 factors25,26
or degradation of Gli124,27,28. Although ubiquitylation is a rele-
vant mechanism to control protein degradation21, it is also
required for a variety of non-proteolytic functions.
Here, we identify a new mechanism of regulation of SuFu. We
show that the HECT E3 ubiquitin ligase Itch, in complex with the
adaptor protein β-arrestin2, binds SuFu and promotes its K63-
linked ubiquitylation. This event does not affect SuFu stability.
Rather, Itch-mediated ubiquitylation of SuFu facilitates the for-
mation of the SuFu/Gli3 complex, increasing the stability of
Gli3FL and, consequently, the amount of Gli3R, thus keeping the
Hh pathway off. Moreover, we demonstrate that the Itch-
dependent ubiquitylation of SuFu has a key protective role in MB
oncogenesis.
Results
The E3 ubiquitin ligase Itch promotes SuFu ubiquitylation. To
identify the molecular mechanisms controlling SuFu activity, we
set out to investigate the role of ubiquitylation in the regulation of
SuFu. First, we tested whether SuFu can be targeted for ubiqui-
tylation by E3 ubiquitin ligases known to modulate Hh signalling,
namely Itch, Nedd4 (HECT E3s), SCFβTrCP, CRL3SPOP,
CRL3REN, and CRL3KCTD21 (Cullin-RING E3s). We found that
only Itch was able to ubiquitylate SuFu (Fig. 1a and Supple-
mentary Fig. 1a, b) in cultured cells. Accordingly, increasing
amounts of Itch induced a progressive increase in the ubiquity-
lation of endogenous SuFu (Fig. 1b), while no effect was observed
with other HECT E3 ligases (Supplementary Fig. 1a, b). To
determine whether SuFu interacts with Itch, we carried out co-
immunoprecipitation experiments and demonstrated that Itch
interacts with both exogenous (Fig. 1c) and endogenous SuFu
(Fig. 1d) in cultured cells. Direct interaction between GST-Itch
and in vitro translated [35S]-labelled SuFu, as well as between
recombinant Itch and GST-SuFu, was also demonstrated by
in vitro pull-down assays (Fig. 1e, f). The modular structural
organisation of Itch consists of an N-terminal Ca2+-dependent
phospholipid-binding C2 domain, four WW domains implicated
in multiple protein–protein interactions, and a C-terminal cata-
lytic HECT domain (Fig. 1g). To identify the speciﬁc domains of
Itch involved in the interaction with SuFu, we performed glu-
tathione S-transferase (GST) pull-down assays using in vitro
transcribed/translated SuFu and different GST-Itch proteins
containing only the HECT catalytic domain, the four WW
domains, or single WW domains (WW1, WW2, WW3, WW4).
We found that the WW1 and WW2 domains of Itch, but not
WW3, WW4, or the HECT domain, directly bind to SuFu
(Fig. 1h–j).
Itch ubiquitylates SuFu by K63 linkage. We next investigated
the ability of Itch to ubiquitylate SuFu both in vivo and in vitro.
In cultured cells, ectopic expression of Itch, but not of the cata-
lytically inactive ItchC830A mutant, induced the ubiquitylation of
endogenous SuFu (Fig. 2a). Moreover, Itch−/− mouse embryonic
ﬁbroblasts (MEFs) displayed decreased ubiquitylation of endo-
genous SuFu when compared to wild-type MEFs (Fig. 2b). SuFu
ubiquitylation was rescued by wild-type Itch, but not by its cat-
alytically inactive mutant (ItchC830A) (Fig. 2b).
The Itch-dependent ubiquitylation of SuFu was conﬁrmed
in vitro. We used puriﬁed recombinant Itch in a reconstituted
in vitro ubiquitylation system containing ubiquitin, E1, E2
(UbcH7), adenosine triphosphate (ATP), and in vitro synthesised
radiolabelled [35S] SuFu as substrate. High levels of SuFu
ubiquitylation were observed in the presence of recombinant
Itch (Fig. 2c), whereas a SuFu mutant in which all lysine residues
were mutated to arginine (SuFu K-less) was not ubiquitylated
(Fig. 2d).
To identify the speciﬁc lysine residues of SuFu that are
ubiquitylated by Itch, we assessed the Itch-dependent ubiquityla-
tion of SuFu mutated in lysine 257, 321, or 457, previously
described as direct (K257) or potential (K321 and K457) SuFu
ubiquitylation sites18,31 (Fig. 2e). We observed a signiﬁcant
reduction in the ubiquitylation of SuFuK321R and SuFuK457R
mutants, as well as the SuFuK321/457R mutant, when compared
to ubiquitylation of wild-type SuFu (Fig. 2f, g and Supplementary
Fig. 2). No decrease was observed in the Itch-mediated
ubiquitylation of SuFu when lysine 257, previously identiﬁed as
a ubiquitin acceptor site that induces SuFu proteasomal
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degradation18, was replaced by arginine (K257R) (Supplementary
Fig. 2). Overall, these results indicate that Itch ubiquitylates SuFu
on lysines 321 and 457.
To determine if Itch-induced ubiquitylation of SuFu primes it
for proteasomal degradation, we examined the effect of the
proteasome inhibitor MG132 on this event. As shown in Fig. 2h,
proteasome inhibition did not cause accumulation of the Itch-
dependent ubiquitylation of SuFu. Accordingly, ectopic expres-
sion of increasing amounts of Itch or its depletion by RNA
interference did not result in any change in the exogenous or
endogenous SuFu protein levels, indicating that the Itch-
dependent ubiquitylation of SuFu does not lead to SuFu
degradation (Fig. 2i–k). Similarly, no changes in the half-life of
SuFu were observed in Itch−/− MEFs compared to wild-type
MEFs (Fig. 2l).
Next, we analysed the molecular mechanism by which Itch
ligates ubiquitin to SuFu. An in vitro ubiquitylation assay
performed in the presence of in vitro transcribed/translated
SuFu, GST-Itch, and ubiquitin (wild type or mutant) showed that
Itch polyubiquitylates SuFu through lysine 63- but not lysine 48-
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mediated linkages. Indeed, while a ubiquitin mutant in which K48
is replaced by arginine (K48R) was efﬁciently ligated to SuFu by
Itch, a ubiquitin mutant in which K63 is replaced by arginine
(K63R) was not linked to SuFu and showed a reduced formation
of high polyubiquitin chains and a pattern similar to the one
observed in the presence of the K-less ubiquitin mutant, in which
all lysine residues are mutated. Accordingly, the ubiquitin mutant
containing only lysine 63 (K63O), but not the ubiquitin mutant
containing only lysine 48 (K48O), was efﬁciently ligated to SuFu
by Itch, similarly to wild-type ubiquitin (Fig. 2m). Similar results
were obtained in in vivo ubiquitylation assays in which the
ectopic expression of K63R ubiquitin, but not of the K48R
ubiquitin mutant, strongly reduced the Itch-dependent ubiquity-
lation of SuFu (Supplementary Fig. 3). Taken together, these
results indicate that Itch catalyzes the assembly of K63-linked
polyubiquitin chains on SuFu and does not target SuFu for
degradation.
Itch-mediated SuFu ubiquitylation affects SuFu–Gli3 interac-
tion. K63-linked polyubiquitin chains are thought to serve a
scaffolding function for signalling proteins and positively regulate
protein complex formation32. We hypothesised that the Itch-
mediated K63-linked polyubiquitylation could regulate the
interaction of SuFu with Gli factors, the ﬁnal effectors of the Hh
pathway. SuFu is known to bind and protect Gli3 from SPOP-
mediated degradation, favouring the generation of a cleaved form
(Gli3R) that has nuclear repressor activity on Hh-dependent gene
expression7,33.
To determine whether the Itch-dependent ubiquitylation of
SuFu increases the association between SuFu and Gli3, we
examined the ability of the SuFuK321/457R mutant to interact
with Gli3. To this regard we carried out a NanoLucR Binary
Technology (NanoBiT) assay, a two-subunit system based on
NanoLucR luciferase used for intracellular detection of
protein–protein interactions34,35. We fused Gli3 and SuFu WT
or the SuFuK321/457R mutant protein to Small BiT (SmBiT) or
Large BiT (LgBiT) subunits, respectively. The interaction of
fusion partners leads to structural complementation of LgBiT
with SmBiT, generating a luminescent signal that is a read-out of
binding strength. As shown in Fig. 3a, we observed a signiﬁcant
reduction of luminescence when we overexpressed Gli3-SmBiT
and SuFuK321/457R-LgBiT mutant compared to wild-type SuFu-
LgBiT, demonstrating a decreased association of Gli3 with
SuFuK321/457R mutant. Of note, the expression of Itch was
able to increase the interaction of Gli3-SmBiT with wild-type
SuFu-LgBiT, but not with the SuFuK321/457R-LgBiT mutant.
The effect of Itch-dependent ubiquitylation of SuFu on the
formation of the SuFu/Gli3 complex was then tested by
immunoprecipitation. Endogenous Gli3 was immunoprecipitated
from cells expressing wild-type SuFu or the SuFuK321/457R
mutant. The SuFuK321/457R mutant displayed a decreased
ability to bind Gli3 when compared to wild-type SuFu, as
measured by the absolute levels of SuFu coimmunoprecipitated
with Gli3 and by the SuFu/Gli3 ratio (Fig. 3b, c). In agreement
with this result, the formation of the SuFu/Gli3 complex was
affected by Itch modulation. While Itch depletion by RNA
interference caused a reduction of the SuFu/Gli3 interaction
(Fig. 3d, e), expression of Itch in Itch−/− MEFs led to increased
formation of the SuFu/Gli3 complex (Fig. 3f, g).
To monitor the possible structural consequence of the K321/
457R mutation in SuFu, as well as its impact on Gli3 binding
afﬁnity, we performed computational studies based on molecular
dynamics (MD) simulations and free energy of binding calcula-
tions. To this aim, we used the available crystallographic structure
of SuFu in complex with a Gli3 peptide (PDB ID: 4BLD) that well
represents a static snapshot of the SuFu/Gli3 interaction at high
resolution (2.8 Å). The results from this study indicate that the
interaction between Gli3 and SuFu is not expected to be impaired
by the K321/457R mutation of SuFu at either the structural or
thermodynamic level (Supplementary Fig. 4).
We also demonstrated by immunoprecipitation followed by re-
immunoprecipitation experiments that SuFu co-purifying with
Gli3 is ubiquitylated (Fig. 3h) and that the strong ubiquitylation
of SuFu observed in the presence of both Gli3 and Itch was
associated with an increased interaction of SuFu with Gli3
(Fig. 3i).
Next, we addressed the role of the Itch-dependent ubiquitylation
of SuFu in the regulation of Gli3. As shown in Fig. 3j, in SuFu−/−
MEFs the steady-state levels of Gli3FL and Gli3R were higher after
the expression of wild-type SuFu than after the expression of the
SuFuK321/457R mutant or in control cells. Moreover, in SuFu−/−
MEFs the half-life of Gli3FL was signiﬁcantly shorter after
expression of the SuFuK321/457R mutant than after expression of
wild-type SuFu (Fig. 3k). In agreement with the ﬁnding that SuFu
potentiates the formation of Gli3R by controlling the rate of Gli3R
production and not the rate of its degradation7, we found that the
half-life of Gli3R remained unchanged. Accordingly, the expression
of the SuFuK321/457R mutant resulted in a reduction of Gli3FL
and of the Gli3R nuclear fraction when compared to Gli3FL and of
the Gli3R nuclear fraction present after the expression of wild-type
SuFu (Fig. 3l). The stability of Gli3 was also investigated in response
to modulation of Itch. As shown in Fig. 3m, the steady-state levels
of Gli3FL and Gli3R were lower after the knockdown of Itch when
compared to the ones in control cells. In agreement with this result,
the expression of Itch, but not of the ItchC830A mutant, in Itch−/−
MEFs led to an increase of Gli3FL stability (Fig. 3n). These data
strongly suggest the role of Itch-mediated ubiquitylation of SuFu in
Fig. 1 Itch ubiquitylates and binds SuFu. a, b HEK293T cells were transfected with plasmids expressing HA-ubiquitin (HA-Ub) in the presence of different
E3 ubiquitin ligases (a) or increasing amount of Flag-Itch (b). Cell lysates were immunoprecipitated with an anti-SuFu antibody, and ubiquitylated forms
were revealed with an anti-HA antibody. c HEK293T cells were co-transfected with Flag-Itch and HA-SuFu as indicated. Interaction between Itch and SuFu
was detected by immunoprecipitation (IP) followed by immunoblot (IB) analysis with the indicated antibodies. d Interaction between endogenous Itch and
SuFu was detected in HEK293T cells by immunoprecipitation followed by immunoblot analysis with the indicated antibodies. e GST-Itch was bound to
glutathione-sepharose beads and used for in vitro pull-down assay. In vitro translated 35S-labelled SuFu was incubated with free GST control or GST-Itch.
After GST pull-down, the protein complex was detected by ﬂuorography. Coomassie blue staining shows the expression levels of recombinant proteins
GST-Itch or GST only. f GST-SuFu was bound to glutathione-sepharose beads and used for in vitro pull-down assay. Untagged Itch recombinant protein
was incubated with free GST control or GST-SuFu. After GST pull-down, the protein–protein interaction was detected by IB with an anti-Itch antibody.
Coomassie blue staining shows the expression levels of recombinant proteins GST-SuFu or GST only. g Schematic representation of Itch and its interaction
with SuFu. h, i GST-HECT (h) or GST-4WWs (i) were bound to glutathione-sepharose beads and used for in vitro pull-down assay with in vitro translated
35S-labelled SuFu. After GST pull-down, protein complexes were analysed by IB. j A GST pull-down assay with GST-WW1, -WW2, -WW3, or -WW4 and
in vitro translated 35S-labelled SuFu was carried out as described in e
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the formation of SuFu/Gli3 complex leading to an increase of
Gli3FL stability, and consequently of the Gli3R amount.
Next, we tested whether SuFu ubiquitylation is involved in the
negative regulation of Hh-dependent gene expression. Figure 3o
shows that overexpression of Gli3 and wild-type SuFu in SuFu−/−
MEFs caused a signiﬁcant reduction of the messenger RNA
(mRNA) levels of Hh target genes. This effect was rescued in the
presence of SuFuK321/457R mutant, indicating that Itch-
dependent SuFu ubiquitylation is relevant for the suppressive
function of SuFu in Hh signalling.
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Hh activation inhibits the Itch-mediated ubiquitylation of
SuFu. To clarify the correlation between SuFu ubiquitylation and
the activity of Hh signalling, we ﬁrst evaluated SuFu ubiquityla-
tion levels during cerebellar development in mice. It is known
that Hh signalling regulates cerebellar development by controlling
the proliferation of granule cell progenitors (GCPs). During the
ﬁrst week of postnatal development, the cerebellum is formed by
an external cortical germinal layer populated by high-
proliferating GCPs, which are sustained by high Hh signalling
as a result of Purkinje cell-derived Shh stimuli. After the ﬁrst
postnatal week, the physiologic withdrawal of Hh signal causes
GCPs growth arrest, their migration in the internal granule layer,
and differentiation into mature granules36,37. We analysed the
ubiquitylation of SuFu and the interaction of SuFu with Gli3 in
the postnatal cerebellum tissues of P2- up to P15-old mice and
found that SuFu ubiquitylation, as well as the SuFu/Gli3 complex,
increased as the pathway is progressively switched off, as indi-
cated by the reduction of the mRNA and protein levels of Gli1, a
major read-out of Hh signalling (Fig. 4a–c). These data suggest
that SuFu ubiquitylation is functionally related to the activity of
Hh signalling. To support this ﬁnding, we analysed SuFu ubi-
quitylation, in the presence or absence of Itch, in NIH3T3 cells
treated with Smoothened agonist (SAG), a known small-molecule
agonist of the Hh pathway. In agreement with the in vivo results,
we observed a reduction of the Itch-dependent ubiquitylation of
SuFu in response to Hh signalling activation induced by SAG
(Fig. 4d).
Overall, these data support a negative role of the Itch-mediated
ubiquitylation of SuFu in the regulation of Hh signalling.
β-Arrestin2 increases the Itch-mediated ubiquitylation of
SuFu. Itch is an E3 ubiquitin ligase whose activity is regulated by
post-translational events such as phosphorylation38 as well as by
proteins that induce its catalytic activity28,39 and by the interac-
tion with adaptor proteins that mediate the recruitment of spe-
ciﬁc substrates40–43. Of note, among these, the multifunctional
adaptor proteins β-arrestins (β-arrestin1 and β-arrestin2) have
emerged as important mediators of the Hh pathway44,45.
Therefore, we tested whether the Itch-dependent ubiquitylation
of SuFu was affected by the presence of β-arrestins. We observed
that ectopic expression of β-arrestin2, but not β-arrestin1, pro-
moted the ubiquitylation of endogenous SuFu (Fig. 5a). More-
over, expression of β-arrestin2 resulted in increased Itch-
mediated ubiquitylation of SuFu as assessed by both in vivo
and in vitro ubiquitylation assays (Fig. 5b, c and Supplementary
Fig. 5). Accordingly, small interfering RNA (siRNA)-mediated
depletion of β-arrestin2 inhibited SuFu ubiquitylation (Fig. 5d).
We also found that β-arrestin2 binds SuFu and that this inter-
action requires Itch (Fig. 5e).
We then expressed tagged SuFu, Itch, and β-arrestin2 in wild-
type MEFs in different combinations. As expected, Flag-tagged
Itch co-immunopuriﬁed both haemagglutinin (HA)-tagged SuFu
and GFP-tagged β-arrestin2. Parallel anti-Flag immunoprecipi-
tates were eluted with Flag peptide and re-immunoprecipitated
with an anti-HA antibody. Again, all three proteins were detected
by immunoblotting of the second immunoprecipitation indicat-
ing that the three proteins, SuFu, Itch, and β-arrestin2, are
assembled in a ternary complex (Fig. 5f). Further, this result
shows that the presence of β-arrestin2 increases the interaction of
SuFu with Itch, as also conﬁrmed by re-expressing β-arrestin2 in
βarr2−/− MEFs (Fig. 5g).
Moreover, in agreement with our previous data indicating that
SuFu ubiquitylation correlates with the activity of the Hh
signalling pathway (Fig. 4), the formation of the SuFu/Itch/β-
arrestin2 complex increased as the pathway is progressively
switched off, as shown in postnatal mouse cerebellum tissues
(Fig. 5h), and was signiﬁcantly reduced when the pathway was
either activated in response to SAG treatment (Fig. 5i, j) or in MB
tumour cells in which the Hh pathway is hyperactivated by
deletion of Ptch repressor46 (Fig. 5k).
Itch-mediated ubiquitylation of SuFu counteracts MB forma-
tion. Several germline and somatic mutations of SuFu have been
identiﬁed in MB patients10,12–17. Recently, whole genome
sequencing of a large cohort of Shh-MBs revealed a high fre-
quency of mutations of Hh pathway genes, including new SuFu
genetic alterations47. Notably, many mutations described so far
occur in the C-terminal region of SuFu thus affecting the K321
and K457 residues, suggesting that alterations in Itch-mediated
SuFu ubiquitylation might play a key role in MB development.
To address the biological role of the Itch-dependent ubiqui-
tylation of SuFu in the regulation of tumour cell growth, we used
human MB Daoy cells belonging to the Shh-MBs subgroup48–50.
We ﬁrst compared the proliferation of human MB Daoy cells
expressing wild-type SuFu, the SuFuK321/457R mutant, or a
control vector. As evaluated by BrdU incorporation and colony-
formation assay, wild-type SuFu, but not the SuFuK321/457R
mutant, was able to inhibit the proliferation of human MB Daoy
cells or decrease the number of colonies (Supplementary Fig. 6a–c).
As expected, the SuFuK321/457R mutant retained its inability to
block cell growth of Daoy cells following Itch or SuFu modulation
(Supplementary Fig. 6e, f). Moreover, we carried out wound
healing assays to determine the effect of the Itch-mediated
ubiquitylation of SuFu on the migration of MB cells. Daoy cells
Fig. 2 Itch ubiquitylates SuFu through K63 linkage. a HEK293T cells were co-transfected with HA-Ub in the presence or absence of Flag-Itch or Flag-
C830A. Cell lysates were immunoprecipitated with an anti-SuFu antibody, followed by immunoblotting with an anti-HA antibody to detect ubiquitylated
forms. b Itch−/− MEFs were transfected with HA-Ub in the presence or absence of Flag-Itch or Flag-C830A. The assay was carried out as described in a.
Wild-type (WT) MEFs were used as control to evaluate the basal ubiquitylation of endogenous SuFu. c, d In vitro translated 35S-labelled SuFu WT (c, d) or
SuFu K-less (d) was incubated alone or in combination with GST-Itch for the indicated times. The ubiquitylated forms were detected by ﬂuorography. e
Schematic representation of SuFu protein showing its lysine residues involved in Itch-dependent ubiquitylation. f, g Flag-SuFu WT or Flag-SuFu mutants
were co-transfected in HEK293T cells with HA-Ub in the presence or absence of Myc-Itch. The assay was carried out as described in a. h HEK293T cells
were transfected with HA-Ub and Flag-SuFu in the presence or absence of Myc-Itch. Transfected cells were treated with MG132 (50 µM for 4 h) to enrich
for ubiquitylated proteins. The assay was carried out as described in a. i HEK293T cells were transfected with Flag-SuFu in the presence or absence of
increasing amount of Myc-Itch. Total protein levels were analysed by immunoblotting. j HEK293T cells were transfected in the presence or absence of
increasing amount of Myc-Itch. Total protein levels were analysed by immunoblotting. k Immunoblotting analysis of SuFu and Itch proteins in
HEK293T cells transfected with control (siCTR) or Itch siRNAs (siItch). β-Actin is shown as a control for loading (*non-speciﬁc bands). l SuFu protein
levels in WT MEF or Itch−/− MEF cells treated with cycloheximide (CHX, 100 µg/ml) at different time points. m Puriﬁed recombinant proteins wild-type
Ub or Ub mutants K48 only (K48O), K48R, K63 only (K63O), K63R, or K-less were incubated with GST-Itch and in vitro translated 35S-labelled SuFu for
the indicated times. Ubiquitylated SuFu was detected by ﬂuorography
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expressing the SuFuK321/457R mutant displayed an increased
motility when compared to cells expressing wild-type SuFu
(Supplementary Fig. 6d).
The effect of the SuFuK321/457R mutant on MB cell growth
was also tested in vivo. To this end, we xenografted human MB
Daoy cells previously infected with control lentiviruses or
lentiviruses carrying wild-type SuFu or the SuFuK321/457R
mutant into NOD/SCID mice. Non-invasiveness T2-weighted
magnetic resonance imaging (MRI) at 41 days after transplanta-
tion showed, as expected, the ability of wild-type SuFu to decrease
the tumour volume. Strikingly, this effect was not observed with
the SuFuK321/457R mutant (Supplementary Fig. 7a, b).
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Moreover, a signiﬁcant decrease of 18F-ﬂudeoxyglucose (FDG)
uptake in mice engrafted with cells expressing wild-type SuFu,
but not in mice engrafted with cells expressing SuFuK321/457 R
mutant, was observed by PET/SPECT/CT imaging (Fig. 6a) and
PET quantiﬁcation (Fig. 6b). Consistently, compared to mice
engrafted with empty lentiviruses, mice engrafted with wild-type
SuFu showed a reduced tumour growth rate, a reduced tumour
volume (at the end point of experiment) (Fig. 6c–e), a decreased
labelling of Ki67 and Gli1 (the ﬁnal downstream target of Hh
signalling) (Fig. 6f, g), and an increased expression of the Gli3
repressor form (Fig. 6h). Notably, all these effects were not
observed in mice engrafted with the SuFuK321/457R mutant.
The effect of the SuFuK321/457R mutant on MB cell growth
in vivo was conﬁrmed in an MB orthotopic xenograft animal
model. Human Daoy cells, previously infected with control
lentiviral particles or lentiviral particles expressing wild-type SuFu
or the SuFuK321/457R mutant, were implanted into the
cerebellum of immunocompromised mice. Assessment of the
tumour volume (calculated along serial histologic brain sections)
demonstrated the failure of the SuFuK321/457R mutant to
decrease the tumour mass as instead observed in wild-type SuFu
mice (Fig. 7a, b). Such an effect was likely caused by the inability
of the SuFuK321/457R mutant to suppress the tumour cell
proliferation as suggested by increased expression of Ki67 and
Gli1 observed in mice engrafted with the SuFuK321/457R mutant
compared to mice engrafted with wild-type SuFu (Fig. 7c, d).
The relevance of Itch-dependent ubiquitylation of SuFu in the
control of tumour growth was also validated in primary MB cells
derived from Ptch+/− mice46. In this mouse model, MB
formation results from the deletion of the Ptch gene that leads
to constitutive activation of the Hh pathway46. Primary MB cells
freshly isolated from Ptch+/− mice were transduced with control
lentiviruses or lentiviruses expressing wild-type SuFu or the
SuFuK321/457R mutant. The proliferation of MB cells was
impaired by expression of wild-type SuFu, but not by expression
of the SuFuK321/457R mutant (Supplementary Fig. 8). Of note,
this result was also conﬁrmed in vivo in primary mouse Ptch+/−
allografts. As expected, compared to mice engrafted with control
lentiviruses, mice engrafted with wild-type SuFu showed a
reduced tumour growth rate, a reduced tumour volume (at the
end point of the experiment), and a decreased Ki67 and Gli1
labelling. Remarkably, these effects were not observed in mice
engrafted with the SuFuK321/457R mutant (Fig. 8a–e).
Collectively, these ﬁndings demonstrate that the Itch-mediated
ubiquitylation of SuFu plays a crucial role for the negative
regulation of Hh signalling and explain how alterations of this
process, caused by SuFu mutations, contribute to MB
oncogenesis.
Discussion
In the last years, SuFu-Gli3 complex has emerged as a major
control node in Hh signalling. However, how the integrity of
SuFu–Gli3 complex is maintained and how SuFu is regulated by
Hh signalling is still poorly understood.
In the present study, we demonstrate that the HECT E3 ligase
Itch in complex with β-arrestin2 ubiquitylates SuFu through K63-
mediated linkages. Itch/β-arrestin2-dependent K63-linked poly-
ubiquitylation of SuFu on lysines 321 and 457 does not trigger
degradation of SuFu; instead, it increases the association of the
SuFu-Gli3 complex driving the synthesis of Gli3R, which in turn
inhibits signal transduction.
Our ﬁndings add further complexity to the regulation of the
Hh pathway by ubiquitylation. Indeed, following phosphorylation
by PKA, GSK3β, and CK1, which generates binding sites for the
SCFβTrCP ubiquitin ligase, Gli1 is completely degraded, whereas
Gli3 and, to a lesser extent, Gli2, undergo partial proteasomal
degradation, leading to the formation of repressor forms that
translocate into the nucleus and inhibit the transcription of Hh
target genes51,52. Downregulation of βTrCP-dependent degrada-
tion of Gli proteins is part of an Hh-induced activation signal by
which Hh maintains a low degradation mode to enable Gli
function24. Conversely, HIB/SPOP, the substrate-receptor subunit
of the CRL3HIB/SPOP ubiquitin ligase, is upregulated by Hh, and
promotes Gli2 and Gli3 degradation thus representing an Hh-
induced negative feedback loop that modulates signalling activ-
ity6,33,53. Further, we have recently reported that PCAF induces
the proteasome-dependent degradation of Gli1 in response to
genotoxic stress29, and described the ubiquitin-dependent pro-
teolysis of Gli1 mediated by Itch and Numb27,28. Itch was also
found to regulate the basal turnover of Ptch154, thus linking this
HECT E3 ligase to different aspects of Hh signalling.
Interestingly, we show that the Itch-induced non-proteolytic
ubiquitylation of SuFu is regulated by the adaptor β-arrestin2, a
member of the arrestin family of proteins involved in numerous
key physiological processes and in cancer progression55–57. β-
Arrestins have been described to have signalling functions, serve
as scaffolds by regulating the internalisation of various types of
Fig. 3 Itch-dependent K63-linked ubiquitylation of SuFu leads to Gli3R formation. a Gli3/SuFu proteins interaction by NanoBiT technology. Itch−/− MEFs
were transfected with indicated plasmids. *P < 0.05, Gli3+SuFu WT versus Gli3; **P < 0.05, Gli3+SuFu WT+Itch versus Gli3+SuFu WT; ***P < 0.05, Gli3
+SuFuK321/457R versus Gli3+SuFu WT. b, c Association between endogenous Gli3 and Flag-SuFu WT or Flag-SuFuK321/457R assayed by determining
the amount of SuFu that co-precipitated with anti-Gli3 antibody or control goat antisera (IgG) from MEFs lysates (b). The ratio of the SuFu signal
to the Gli3FL signal from b was plotted (c). *P < 0.05. d–g Gli3/SuFu, interaction, assessed as in (b), in WT MEFs transfected with siItch or siCTR (d) or
in Itch−/− MEFs transfected with the indicated plasmids (f). The ratio of the SuFu signal to the Gli3FL signal from (d) and (f) was plotted (respectively
(e) and (g)). *P < 0.05. h WT MEFs were co-transfected with indicated plasmids in the presence or absence of Itch. Cell lysates were immunoprecipitated
with anti-Flag agarose beads (1st IP). After two elutions with Flag peptide, cell lysates were re-immunoprecipitated with anti-HA agarose beads (2nd IP),
followed by immunoblotting as indicated. i WT MEFs were co-transfected with the indicated plasmids. Cell lysates were immunoprecipitated with anti-HA
antibody followed by immunoblotting as indicated. j Gli3FL and Gli3R protein levels in SuFu−/− MEFs before and after expression of SuFu WT or
SuFuK321/457R. k Gli3 half-life in SuFu−/− MEFs after cycloheximide treatment. Gli3FL and Gli3R protein levels were analysed by immunoprecipitation
from whole-cell lysates. The graph shows densitometric analysis. *P < 0.05, SuFu WT versus empty vector; **P < 0.05, SuFuK321/457R versus SuFu WT. l
Subcellular fractions generated from WT MEFs transfected with Flag-SuFu WT or Flag-K321/457R. Lamin B and Tubulin were used as nuclear and
cytoplasmic markers, respectively. m Gli3FL and Gli3R protein levels in WT MEFs transfected with siCTR or siItch. n Gli3 half-life in Itch−/− MEFs
transfected as indicated and then treated with cycloheximide for the indicated times. The graph shows densitometric analysis. *P < 0.05, Itch versus
pcDNA; **P < 0.05, C830A versus Itch. o The graphs show the mRNA levels of the indicated Hh target genes in SuFu−/−MEFs transfected with Gli3 alone
or in combination with Flag-SuFu WT or Flag-K321/457R. *P < 0.05, Gli3+SuFu WT versus Gli3; **P < 0.05, Gli3+SuFuK321/457R versus Gli3+SuFu WT.
*Non-speciﬁc band. Each experiment was performed three times independently. Error bars indicate SD. P-values were determined using Student’s t-test
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receptors, or allow E3 ubiquitin ligase recruitment58. Here, we
show that expression of β-arrestin2 increases the Itch/SuFu
interaction and enhances the Itch-dependent ubiquitylation of
SuFu and that, conversely, knockdown of β-arrestin2 inhibits
these processes. Biochemical data also demonstrate that β-
arrestin2, Itch, and SuFu form a trimeric complex that is
promptly dissociated in response to Hh activation. These
observations support a new additional role of β-arrestin2 in Hh
signalling. β-Arrestin2 has been identiﬁed as an important reg-
ulator of the Hh pathway that activates signalling by promoting
Smo movement to the primary cilium44,45. This potential dual
role of β-arrestin2 would be similar to that of the type-II kinesin
motor protein Kif3a, which, in the absence of Shh, promotes
conversion of Gli3 into a truncated repressor form59, and in the
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Fig. 4 Itch-dependent ubiquitylation of SuFu is reverted by Hh pathway activation. a Cerebellum lysates from CD1 mice killed at 2d, 4d, 7d, 10d, 12d, and
15d postpartum (P2, P4, P7, P10, P12, P15) were immunoprecipitated with an anti-SuFu antibody and immunoblotted with an anti-Ub antibody. Gli3 proteins
were only detected after enriching its levels by immunoprecipitation with an anti-Gli3 antibody. b The graph shows the mRNA levels of Gli1 gene, as a
control of pathway activation, in the cerebella described in a. Error bars indicate SD from three independent experiments. *P < 0.05 (Student’s t-test). c
Association between endogenous Gli3 and SuFu from cell lysates of CD1 mice cerebellum (P3, P7, P10, P15) immunoprecipitated with an anti-Gli3 antibody.
d Itch-dependent SuFu ubiquitylation is inhibited by activation of the Hh pathway. NIH3T3 cells were transfected with HA-Ub in the presence or absence of
Myc-Itch and treated with SAG (200 nM for 6 h). Cell lysates were immunoprecipitated with an anti-SuFu antibody and immunoblotted with an anti-HA
antibody
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presence of Shh and in association with β-arrestin2 promotes Gli
activator formation by transporting Smo into cilia45. We spec-
ulate that β-arrestin2 might regulate the switch between pathway
OFF, promoting Itch-dependent SuFu ubiquitylation and Gli3R
formation, and pathway ON, triggering the formation of the Smo/
β-arrestin2/Kif3a complex.
Mutations in SuFu are a feature of the Shh-MB subgroup.
Germline and somatic mutations of SuFu described in patients
with medulloblastoma alter SuFu repressor functions. Indeed,
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some of these mutations generate truncated proteins that are
unable to bind Gli factors17, thus leading to aberrant activation of
Hh signalling. Kool et al.47 recently reported the genome
sequencing of the largest series to date of Shh-related MBs.
Interestingly, this group identiﬁed two novel non-sense SuFu
mutations, Y424X and W430X, both lacking lysine 457 here
identiﬁed as required for the Itch-dependent ubiquitylation of
SuFu (Supplementary Fig. 9a). We have now shown that these
mutations encode truncated proteins that conserve Gli consensus,
but are unable to be ubiquitylated by Itch (Supplementary
Fig. 9b). Accordingly, SuFuY424X or SuFuW430X display a
reduced ability to bind Gli3 (Supplementary Fig. 9c), cause a
decrease in the abundance of nuclear Gli3R when compared to
wild-type SuFu (Supplementary Fig. 9d), and hamper the ability
of SuFu to inhibit MB cell growth (Supplementary Fig. 9e). These
ﬁndings support our model (Fig. 9) that the impairment of SuFu
ubiquitylation is implicated in MB oncogenesis.
In conclusion, the Itch-dependent non-proteolytic ubiquityla-
tion of SuFu identiﬁed in our study represents a novel mechanism
that inhibits the Hh signalling pathway and indicates that
alterations of this process, caused by SuFu mutations that make it
insensitive to Itch-mediated ubiquitylation, contribute to the
pathogenesis of MB.
Methods
Plasmids. pcDNA-Flag-Gli3, pCXN-Flag-RENKCTD11, pCXN-Flag-KCTD21,
pcDNA-Itch, GST-SuFu, pCHN3HA-SuFu, pCHN3HA-SuFu-W430X and -Y424X
constructs were generated in our lab with standard cloning techniques and veriﬁed
by sequencing. SuFu mutants (SuFuK321/457R, SuFuK321R, SuFuK257R,
SuFuK457R) were generated using the QuickChange II site-directed mutagenesis
kit (Agilent Technologies, Santa Clara, CA, USA) and veriﬁed by sequencing. The
following plasmids were kindly provided by other labs: pcDNA-Myc-Itch, pcDNA-
Myc-Nedd4, pcDNA-Myc-Ubiquitin (M. Alimandi), pCMV2-Flag-Itch, -Flag-
C830A (A. Angers), GST-Itch, GST-HECT, GST-4WWs, GST-WW1, GST-WW2,
GST-WW3, GST-WW4, pcDNA-Flag-WWP1 (G. Melino), HA-Ubiquitin con-
structs (I. Dikic), pRK5-Flag-SuFu (M. Merchant), pcDNA3.1-Flag-SPOP (Wang
B), pcDNA-Flag-βTrCP, and pcDNA-Flag-Skp2 (M. Pagano). pcDNA3-HA-β-
arrestin1, pcDNA3-HA-β-arrestin2, pEGFP-N1-β-arrestin2, and pRK-Myc-Smurf
were purchased from Addgene (Cambridge, MA, USA), and pLenti-GIII-CMV-
SuFu-GFP-2A-PURO and pLenti-GIII-CMV-GFP-2A-PURO-Blank were pur-
chased from Applied Biological Materials (Richmond, BC, CA).
Antibodies and reagents. Rabbit anti-SuFu C81H7 (#2522S, 1:3000), rabbit anti-
β-arrestin2 C16D9 (#3857S, 1:1000), and mouse anti-Gli1 L42B10 (#2643S, 1:500)
were from Cell Signalling (Beverly, MA, USA); goat anti-SuFu C-15 (sc-10933 2
μg), mouse anti-GST B-14 (sc-138, 1:10,000), goat anti-Actin I-19 (sc-1616,
1:1000), goat anti-Lamin B M-20 (sc-6217, 1:1000), mouse anti-α Tubulin TU-02
(sc-8035, 1:1000), mouse anti-Ub P4D1 (sc-8017, 1:500), rabbit anti-Gli1 H300 (sc-
20687, 1:100), mouse anti-HA-probe F-7 horseradish peroxidase (HRP) (sc-7392
HRP, 1:1000), mouse anti-c-Myc 9E10 HRP (sc-40 HRP, 1:500), mouse anti-GFP
(B-2) HRP (sc-9996 HRP, 1:1000), and HRP-conjugated secondary antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Flag M2
HRP (A8592, 1:1000), anti-Flag M2 agarose (A2220, 1–2 μg), and anti-HA agarose
(A2095, 1–2 μg) were from Sigma Aldrich (St Louis, MO, USA); goat anti-Gli3
(AF3690, 1:1000 or 2–4 μg) and goat anti-Gli2 (AF3635, 1:1000) were from R&D
Systems (Minneapolis, MN, USA); mouse anti-Itch (611199, 1:2000) antibody was
purchased from BD Bioscience (Heidelberg, Germany); rabbit anti-Ki67 SP6
(MA5-14520, 1:100) was from Thermo Fisher Scientiﬁc (Waltham, MA, USA);
mouse anti-MDM2 OP46 (Ab-1, 1:500) was from Calbiochem (Darmstadt, Ger-
many). Where indicated, cells were treated with SAG (200 nM, Alexis Biochemicals
Farmingdale, NY, USA) for 6 h, MG132 (50 µM; Calbiochem, Nottingham, UK) for
4 h, or Cycloheximide (CHX 100 µg/ml, Sigma Aldrich).
Cell culture and transfection and lentiviral infection. HEK293T cells, wild-type
MEFs, SuFu–/–, Itch–/–, and βArr2−/– MEFs were cultured in Dulbecco’s modiﬁed
Eagle’s medium plus 10% fetal bovine serum (FBS) or 10% bovine serum (BS) for
NIH3T3 cells. Daoy cells were maintained in Eagle’s minimum essential medium
(MEM) plus 10% FBS. All media contained L-glutamine and antibiotics.
Primary MB cells were freshly isolated from Ptch+/− mice as previously
described60. Cells were cultured in Neurobasal Media-A with B27 supplement
minus vitamin A61. HEK293T (CRL-3216™), NIH3T3 (CRL-1658™), and Daoy
(HTB-186™) cells were obtained from ATCC. Itch–/– MEFs were a gift from Dr C.
Brou (Institut Pasteur), SuFu–/– MEFs were a gift from Dr R. Toftgård (Karolinska
Institutet), and βArr2−/– MEFs were a gift from Dr R.J. Lefkowitz (Howard Hughes
Medical Institute).
Mycoplasma contamination in cell cultures was routinely detected by using
PCR detection kit (Applied Biological Materials, Richmond, BC, Canada).
Transient transfections were performed using DreamFectTMGold transfection
reagent (Oz Biosciences SAS, Marseille, FR) or Lipofectamine® with PlusTM
Reagent (Thermo Fisher Scientiﬁc, Waltham, MA, USA) in accordance with the
manufacturer’s protocols. For lentiviral infection, HEK293 cells were transfected
with lentiviral constructs and the packaging plasmids pMD.G and pCMVR8.74
using Calcium/Phosphate precipitation. Culture medium containing the lentivirus
was collected 48 and 72 h after transfection. Daoy cells were infected with puriﬁed
lentiviruses for 48 h in the presence of 4 µg/ml polybrene (Sigma Aldrich, St Louis,
MO), primary MB cells were infected with puriﬁed lentiviruses for 48 h, and SuFu–/–
MEFs were infected with lentiviruses in the presence of 8 µg/ml polybrene for 72 h.
For RNA interference, scrambled (Cat no: D-001810-10-05), Itch (Cat no: L-
007196-00-0005), SuFu (Cat no: E-015382-00), or β-arrestin2 (Cat no: J-041022-11
and J-041022-10) short interfering RNA oligos (Dharmacon, Inc., Lafayette, CO,
USA) were transfected for 48 h using Lipofectamine 2000® (Thermo Fisher
Scientiﬁc) or HiPerFect Transfection Reagent (Qiagen, Milan, IT).
GST pull-down assay. Recombinant GST-fusion proteins were expressed in
Escherichia coli BL21, and puriﬁed as previously described62. GST, GST-SuFu, and
GST-Itch recombinant proteins were bound to glutathione beads (GE Healthcare,
Pittsburgh, PA, USA) and incubated for 2 h with in vitro translated protein in
binding buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 20 mM, MgCl2
2 mM, KCl 100 mM, 20% glycerol, EDTA 0.2 mM, 0.05% NP-40) and analysed by
immunoblotting or ﬂuorography. As an alternative, GST or GST-SuFu recombi-
nant proteins bound to glutathione beads were incubated for 2 h with untagged
Fig. 5 β-arrestin2 increases the Itch-dependent SuFu ubiquitylation. a WT MEFs were transfected with Flag-Ub in the presence or absence of HA-β-
arrestin1 (HA-βArr1) or HA-β-arrestin2 (HA-βArr2). Cell lysates were immunoprecipitated with an anti-SuFu antibody and ubiquitylated forms were
revealed with an anti-Flag antibody. b HEK293T cells transfected with the indicated plasmids were immunoprecipitated with an anti-SuFu antibody.
Ubiquitylated forms were revealed with an anti-HA antibody. c In vitro translated 35S-labelled SuFu was incubated alone or in combination with untagged
recombinant Itch protein in the presence or absence of recombinant β-arrestin2 protein for the indicated times. Levels of ubiquitylated 35S-labelled SuFu
were detected by ﬂuorography. d SuFu ubiquitylation in WT MEFs transfected with HA-Ub in the presence or absence of Myc-Itch and with speciﬁc siRNA
for β-arrestin2 (siβArr2) or non-speciﬁc control (siCTR). Immunoprecipitation and immunoblotting were performed as in (b). e HEK293T cells were co-
transfected with the indicated plasmids. Interaction of β-arrestin2 with SuFu and Itch was detected by immunoprecipitation followed by immunoblot
analysis with the indicated antibodies. f SuFu, Itch, and β-arrestin2 form a trimeric complex. WT MEFs were transfected with different combinations of
Flag-Itch, GFP-β-arrestin2, and HA-SuFu constructs. Protein lysates were immunoprecipitated with anti-Flag agarose beads. One-third of
immunocomplexes was probed with antibodies to the indicated proteins (1st IP), whereas two-thirds were subjected to two elutions with Flag peptide and
re-immunoprecipitated with HA-agarose beads followed by immunoblotting as indicated (2nd IP). g β-Arrestin2−/−MEF cells were transfected with HA-β-
arrestin2 plasmid. Interaction of Itch with SuFu and β-arrestin2 was detected by immunoprecipitation followed by immunoblot analysis with the indicated
antibodies. h Association of endogenous Itch with SuFu and β-arrestin2 from cell lysates of CD1 mice cerebellum (P3, P7, P10, P15) immunoprecipitated
with an anti-Itch antibody. i, j NIH3T3 cells transfected with the indicated plasmids were treated with SAG (200 nM for 6 h) or vehicle only. Interaction
between Flag-Itch and HA-SuFu (i) or HA-β-arrestin2 (j) was detected by anti-Flag immunoprecipitation, followed by immunoblot analysis with the
indicated antibodies. k Association of endogenous Itch with SuFu and β-arrestin2 from cell lysates of CD1 mice cerebellum (P10) and from MB Ptch+/−
tissue both immunoprecipitated with an anti-Itch antibody
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Fig. 6 Human Daoy MB xenografts. a PET/CT images of representative CTR (n= 6), SuFu WT (n= 6), and SuFu K321/457R (n= 8) mice showing tumour
FDG (F-18-ﬂuorodeoxyglucose) uptake at 41 days after implantation. ROI (region of interest) drafts the tumour mass. Signiﬁcant differences were observed
between SuFu WT and SuFu K321/457R mutant mice. U urinary bladder, M femoral muscle. b Graphic representation of SUV (standard uptake value). For
each tumour, the SUV as mean tumour FDG uptake normalised for animal body weight was calculated. Signiﬁcant difference in tumour FDG uptake was
observed between SuFu K321/457R and SuFu WT mice. *P < 0.05, SuFu WT versus CTR; **P < 0.05, SuFu K321/457R versus SuFu WT. c Images of
xenografted NOD/SCID mice with bilateral MB xenograft tumours. Tumour volume in SuFu K321/457R mutant mice is visually bigger than SuFu WT (scale
bars= 5mm). d Tumour volumes were monitored over time by caliper measurements at the indicated times. *P < 0.01, SuFu WT versus CTR; **P < 0.01,
SuFu K321/457R versus SuFu WT. e Tumour volumes were measured post explantation. *P < 0.01, SuFu WT versus CTR; **P < 0.01, SuFu K321/457R
versus SuFu WT. f Immunohistochemistry of Ki67 and Gli1 stainings. Scale bars indicate 50 µm. g Quantiﬁcation of Ki67 and Gli1 stainings from
immunohistochemistry. *P < 0.01, SuFu WT versus CTR and **P < 0.01, SuFu K321/457R versus SuFu WT. h Western blot analysis shows protein
expression levels. Error bars indicate SD. P-values were determined using Mann–Whitney U-test
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recombinant protein Itch (Boston Biochem Cambridge, MA, USA) in binding
buffer and analysed by immunoblotting.
Immunoblot analysis and immunoprecipitation. Transfected cells were lysed in a
solution containing 50 mM Tris at pH 7.4, 300 mM NaCl, 2% NP-40, 0.25%
deoxycholic acid sodium, 1 mM dithiothreitol (DTT), and protease inhibitors or in
RIPA buffer (50 mM Tris at pH 7.6, 150 mM NaCl,0.5% deoxycholic acid sodium,
5 mM EDTA, 0.1% SDS,100 mM NaF, 2 mM NaPPi, 1% NP-40). The lysates were
centrifuged at 13,000×g for 30 min and the resulting supernatants were subjected to
immunoblot analysis or immunoprecipitation. For immunoprecipitation, cell
lysates were immunoprecipitated with speciﬁc antibodies: anti-Flag and anti-HA
agarose or anti-Gli3, anti-SuFu, and anti-Itch antibodies from 2 h to overnight at 4 °C
with rotation. Flag- or HA-peptide (0,1 mg/ml, Sigma Aldrich) or IgG (1–2 µg,
Santa Cruz Biotechnology) were used as a control. The immunoprecipitations
performed by the use of primary antibodies not conjugated to agarose beads were
followed by incubation with Protein G- or Protein A-agarose beads (Santa Cruz
Biotechnology) for 1 h with rotation63. The immunoprecipitates were then washed
ﬁve times with the lysis buffer described above, resuspended in sample loading
buffer, boiled for 5 min, resolved in sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS-PAGE), and then subjected to immunoblot analysis.
Uncropped images of the most important blots were shown in the Supplementary
Figures.
Subcellular fractionation. Subcellular fractionation experiments were performed
as previously described7. Brieﬂy, freshly collected cells were washed twice with
phosphate-buffered saline (PBS) and twice with 10 mM HEPES (pH 7.4) and then
were incubated for 10 min in 10 mM HEPES (pH 7.4). Subsequently, the cells were
lysed in SEAT Buffer (10 mM triethanolamine/acetic acid at pH 7.4, 250 mM
sucrose, 1× EDTA protease inhibitor cocktail) by 15 passages through a 25-G
needle. The lysates were centrifuged at 900×g for 5 min and the resulting super-
natants were brought to 1× buffer A (50 mM Tris at pH 7.4, 300 mM NaCl, 2% NP-
40, 0.25% deoxycholic acid sodium, 1 mM DTT, and protease inhibitors), extracted
for 1 h, and clariﬁed by centrifugation at 20,000×g for 1 h to obtain the citoplas-
matic fraction. On the other side, the nuclear pellets were washed once in SEAT
buffer. The nuclei were extracted for 1 h with 20 mM HEPES at pH 7.9, 1 mM
MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 20% glycerol, 1% Triton X-100, 1 mM DTT,
benzonase, and a protease inhibitor cocktail and clariﬁed by centrifugation at
20,000×g for 1 h. An equal percentage of nuclear and cytoplasmic fractions were
loaded for lane to ensure that equal amounts of each fraction were loaded on the
gel.
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Fig. 7 Human Daoy orthotopic MB xenografts. a Representative images of haematoxylin and eosin (H&E), Ki67, and Gli1 immunohistochemical stainings of
a human Daoy MB cell-derived orthotopic tumour in NOD/SCID mice (n= 6 mice for each group, CTR, SuFu WT, and SuFu K321/457R). Scale bars
represent 500 µm for H&E staining and 50 µm for Ki67 and Gli1 stainings. b Representative tumour average volumes after explantation. c, d Quantiﬁcation
of Ki67 (c) and Gli1 (d) stainings from immunohistochemistry shown in (a). *P < 0.01, SuFu WT versus CTR; **P < 0.01, SuFu K321/457R versus SuFu WT.
Error bars indicate SD. P-values were determined using Mann–Whitney U-test
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In vivo ubiquitylation assay. In vivo ubiquitylation experiments were performed
as previously described29. MEFs or HEK293T cells transfected with various plas-
mids were lysed with denaturing buffer (1% SDS, 50 mM Tris at pH 7.5, 0.5 mM
EDTA, 1 mM DTT) to disrupt protein–protein interactions and then lysates were
diluted 10 times with lysis buffer and subjected to immunoprecipitation with
antibodies indicated in ﬁgures from 2 h to overnight at 4 °C. The immunopreci-
pitated proteins were then washed ﬁve times with the lysis buffer described above,
resuspended in sample loading buffer, boiled for 5 min, resolved in SDS-PAGE,
and then subjected to immunoblot analysis. Polyubiquitylated forms were detected
using anti-HA, anti-Flag, anti-Myc, or anti-Ubiquitin antibodies.
In vitro ubiquitylation assay. In vitro ubiquitylation was performed as previously
described64,65. In vitro translated protein SuFu, produced using TnT® Coupled
Wheat Germ Extract System (Promega, Madison, WI, USA), was incubated at 30 °C
with GST or Itch-GST or Itch-GST and βarr2-GST 400ng (Abnova, Heidelberg,
Germany), 50 mM Tris-HCl at pH 7.5, 5 mM MgCl2, 200 µM okadaic acid, 2 mM
ATP, 0.6 mM DTT, 1 mM ubiquitin aldehyde, E1, UbcH7, and either wild-type or
mutant ubiquitin (Boston Biochem). Polyubiquitylated products were subjected to
SDS-PAGE and detected by ﬂuorography.
NanoLuc Binary Technology assay. Gli3, SuFu WT, and SuFuK321/457R were
cloned into vectors compatible with the Flexi Vector System (NanoBiT™, Promega)
in accordance with the manufacturer’s protocols. For our assay we used Gli3
protein fused to the SmBiT subunit and SuFu WT or SuFuK321/457R mutant
protein fused to LgBiT subunit. Itch–/– MEFs cells were seeded in 96-well plates
and transfected with the plasmids or with the NanoBiT Negative Control Vector,
which encodes HaloTag-SmBiT used in combination with SuFu WT-LgBiT or
SuFu K321/457R-LgBiT. At 24 h post transfection, the Nano-Glo Live Cell Reagent
was added to a 1× concentration and luminescence was measured using the Glo-
Max Multi+Detection System (Promega).
mRNA expression analysis. Total RNA was isolated with TRIzol (Thermo Fisher
Scientiﬁc) and reverse-transcribed with SensiFASTcDNA Synthesis Kit (Bioline
Reagents Limited, London, UK). Quantitative real-time PCR (Q-PCR) analysis of
Gli1, Gli2, Hip1, CyclinD1, CyclinD2, Igf2, and Bmp2 mRNA expression was per-
formed on each complementary DNA (cDNA) sample using the ViiATM 7 Real-
Time PCR System (Life Technologies, Foster City, CA, USA). A reaction mixture
containing cDNA template, SensiFASTTM Probe Lo-ROX mix (Bioline Reagents
Limited), and primer probe mixture was ampliﬁed using standard Q-PCR thermal
cycler parameters. Each ampliﬁcation reaction was performed in triplicate and the
average of the three threshold cycles was used to calculate the amount of transcript
in the sample (using SDS version 2.3 software). mRNA quantiﬁcation was
expressed, in arbitrary units, as the ratio of the sample quantity to the calibrator.
All values were normalized with two endogenous controls, β-2 microglobulin and
HPRT, which yielded similar results.
Cell proliferation and wound healing assays. Cell proliferation was evaluated by
BrdU detection (Roche, Welwyn Garden City, UK). Brieﬂy, after the BrdU pulse
cells were ﬁxed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-
100, and BrdU detection was performed according to the manufacturer’s instruc-
tions. Nuclei were counterstained with Hoechst reagent. At least 500 nuclei were
counted in triplicate, and the number of BrdU-positive nuclei was recorded. For
colony-formation assays, 1 × 104 Daoy cells, infected with lentiviral particles, were
plated in 10-cm-diameter dishes, and after 2 weeks of puromycin (Sigma Aldrich)
selection, cell colonies were counted in triplicate after staining in 20% methanol
and crystal violet. Cells were counted in triplicate. For wound healing assay Daoy
cells, were infected with lentiviral particles and then seeded at high density into 12-
multiwell plates. The following day, a linear scratch in the conﬂuent cell monolayer
was made with a sterile pipette tip. Cells were washed three times with PBS with
Ca2+ and Mg2+ and incubated in regular media. For each well, three pictures were
taken along the scratch area at the indicated times, and the wound areas were
calculated using ImageJ. Cell migration was deﬁned as the reduction of the wound
area in each photographed ﬁeld during the course of the treatment.
Animal studies. For xenograft models, 4 × 106 Daoy cells infected with lentiviral
particles were resuspended in an equal volume of MEM medium and Matrigel (BD
Biosciences, Heidelberg, Germany) and injected subcutaneously (s.c.) at the pos-
terior ﬂank of 6-week-old female NOD/SCID mice (n= 6 CTR, n= 6 SuFu WT,
n= 8 SuFuK321/457R) (Charles River Laboratories, Lecco, Italy). After 40 days
following tumour cells injection, animals were imaged using a dedicated whole
body mouse coil in a 1T MRI scanner (Bruker, Icon, Germany). Mice were
anaesthetised with 1–2% isoﬂuorane in air and O2. During measurements,
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Fig. 8 Mouse Ptch1+/− MB allografts. a Images of representative CTR, SuFu WT, and SuFu K321/457R ﬂank allograft masses (n= 6 mice for each group)
(scale bars= 5 mm). b Tumour volumes were monitored over time by caliper measurements at the indicated times. *P < 0.05, SuFu WT versus CTR; **P <
0.05, SuFu K321/457R mutant versus SuFu WT. c Tumour volumes were measured post explantation. *P < 0.05, SuFu WT versus CTR; **P < 0.05, SuFu
K321/457R mutant versus SuFu WT. d Immunohistochemistry of Ki67 and Gli1 stainings. Scale bars indicate 50 µm. e Quantiﬁcation of Ki67 and
Gli1 stainings from immunohistochemistry. *P < 0.05, SuFu WT versus CTR and **P < 0.05, SuFu K321/457R mutant versus SuFu WT, for Ki67 staining
quantiﬁcation. *P < 0.05, SuFu WT versus CTR and **P < 0.01, SuFu K321/457R versus SuFu WT, for Gli1 staining quantiﬁcation. Error bars indicate SD. P-
values were determined using Mann–Whitney U-test
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respiration was monitored with a sensor connected to an ECG/respiratory unit. T2-
weighted MR scans with Fast Spin-Echo RARE sequence (TR/TE= 2500/35 ms,
number of average (NA= 2)), were acquired for the tumour volume evaluation.
Animals were imaged with a PET/SPECT/CT scanner (Trifoil Imaging, USA)
equipped with gas anaesthesia, respiratory monitoring, and heated bed. Mice were
injected with 9.43MBq (SD 1.26; range 7.43–11.61 MBq) of 18F-FDG (AAA, Italy).
PET imaging started 45 min after FDG injection and lasted 30 min. Positron
emission tomography (PET) images were corrected for decay, randoms, dead time,
and computed tomography (CT) attenuation, and reconstructed using an OSEM
algorithm with 8 subsets and 30 iterations. PET quantitative data were obtained by
an investigator blinded to the group identity by outlining the tumours directly on
the anatomical CT images. At the end of PET experiment, animal were killed with
an overdose of anaesthetic, the tumours were collected, and the volume (mm3) of
each tumour measured with a caliper and calculated by the formula (length2 ×
width) / 2 where length refers to the smaller dimension.
For orthotopic xenografts model, Daoy cells (prepared from fresh culture to
ensure optimal viability of cells during tumour inoculation) infected with
lentiviruses particles were stereotaxically implanted (2 × 105) into the cerebellum of
6-week-old female NOD/SCID mice (n= 6 animals per group) (Charles River
Laboratories) as previously described66. Brain tumour volume calculation was
performed as described in ref. 66.
For allograft models, spontaneous MB from Ptch1+/− mice was isolated,
minced, and pipetted to obtain a single-cell suspension, as previously described67
and then infected with lentiviral particles. Equal volumes of cells (2 × 106) were
injected s.c. at the posterior ﬂank of 6-week-old female BALB/c nude mice (nu/nu)
(n= 6 animals per group) (Charles River Laboratories). Tumour growth was
monitored by measuring the size by caliper and calculated as above describe. All
animal experiments were approved by local ethic authorities and conducted in
accordance with Italian Governing Law (D.lgs 26/2014; Prot. no. 03/2013). Animals
were housed in the Institute’s Animal Care Facilities, which meet international
standards and were checked regularly by a certiﬁed veterinarian responsible for
health monitoring, animal welfare supervision, and revision of experimental
protocols and procedures.
Immunohistochemistry. The 4 μm thick sections were prepared from parafﬁn-
embedded tissues and immunostained with anti-Gli1 or anti-Ki67 antibodies. After
washes, secondary biotinylated antibodies were applied. Binding of antibodies was
detected with the Mouse to Mouse HRP (DAB) Staining System (Scytek Labora-
tories, Inc., Logan, UT, USA) according to the manufacturer’s protocol.
Molecular dynamics. The crystallographic structure of SuFuWT/Gli3 complex
coded by PDB ID: 4BLD68 was used as starting point in MD simulations. Parti-
cularly, chain A was selected, and structural gaps were ﬁlled. For larger portions
such as the IDR disordered region, a preliminary folding experiment was per-
formed starting from a linear sequence of residues. WT and mutant SuFu/Gli3
complexes were solvated in a rectilinear box of TIP3P water molecules buffering 12
Å from the protein. MD simulations were performed according to the procedure
described previously66,69, but in this case unrestrained trajectories were initially
equilibrated for 50 ns and then produced for 200 ns. Free energy of binding of Gli3
to SuFu WT and K321457R double mutant was estimated by the Molecular
Mechanics Generalised Born Surface Area (MM-GBSA) approach70.
Statistical analysis. Statistical analysis was performed using the StatView
4.1 software (Abacus Concepts, Berkeley, CA, USA). Statistical tests were appro-
priately chosen for each experiment. For in vivo studies statistical differences were
analysed by Mann–Whitney U-test for non-parametric values and a P < 0.05 was
considered signiﬁcant. For all other experiments, P-values were determined using
Student’s t-test and statistical signiﬁcance was set at P < 0.05. Results are expressed
as mean ± SD from an appropriate number of experiments (at least three biological
replicas).
Data availability. All data supporting the ﬁndings of this study are within the
Article and Supplementary Files, or available from the authors upon request.
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